Streetbeat News

AGRX

Agile Therapeutics Inc

https://www.agiletherapeutics.com/

CEO

Alfred Altomari

Employees

Industry

Pharmaceutical Preparation Manufacturing

agile therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. our lead product candidate, twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as ag200-15, is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. twirla is based on our proprietary transdermal patch technology, called skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. for more information, please visit the company website at www.agiletherapeutics.com. connect with us on twitter at @agilether.

Open

1.48

Mkt cap

10M

Volume

119K

High

1.51

P/E Ratio

-0.89

52-wk high

2.63

Low

1.44

Div yield

N/A

52-wk low

0.20

Maxim Group analyst Naz Rahman downgraded Agile Therapeutics (NASDAQ:AGRX) from Buy to Hold, indicating a change in the firm's outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 12:56 pm

Agile Therapeutics' stock price increased following the announcement that the company has fully paid off its debt facility with Perceptive Advisors.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 1:29 pm

In Wednesday's pre-market session, health care stocks showed significant movement. NuCana, Kintara Therapeutics, Agile Therapeutics, Compass Therapeutics, HUTCHMED, and Qilian Intl Hldg Gr were among the gainers, with NuCana leading by surging 110.6%. On the downside, P3 Health Partners, 180 Life Sciences, CryoPort, Renalytix, Celularity, and Inspire Veterinary were the losers, with P3 Health Partners dropping 14.7%. CryoPort's decline was noted alongside its Q4 earnings report release.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 1:06 pm

Agile Therapeutics has fully repaid its debt facility with Perceptive Advisors, focusing on expanding Twirla and advancing its business plan.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:42 am

France has made history by becoming the first country to explicitly include abortion rights in its constitution, according to a report by the Washington Post. This landmark decision could have implications for companies involved in women's health and reproductive products.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 5:53 pm

Etsy shares fell by around 8% after reporting mixed Q4 financial results, missing earnings estimates but beating sales forecasts. Other stocks showed significant movements, with La Rosa Holdings, BuzzFeed, and Monopar Therapeutics among the top gainers, while Draganfly, Greenbrook TMS, and Synaptogenix led the losers. Notable movements were also seen in companies like Rivian Automotive, Lucid Group, and Sunnova Energy due to various announcements and financial results.

Portfolio Pulse from Avi Kapoor

February 22, 2024 | 6:38 pm

Agile Therapeutics Inc (NASDAQ:AGRX) shares surged during Thursday's trading session, with a volume of 9.91 million compared to its average of 78.141K. The company announced the immediate exercise of warrants to purchase up to 3.89 million shares at a reduced price of $1.25 per share, expecting gross proceeds of approximately $4.8 million. Additionally, new unregistered warrants to purchase up to 7,785,144 shares at $1.00 per share will be issued. AGRX shares rose 2.80% to $1.02, with a premarket peak at $2.68.

Portfolio Pulse from Vandana Singh

February 22, 2024 | 6:26 pm

Agile Therapeutics has announced the exercise of warrants which has resulted in $4.8 million in gross proceeds. This financial move could potentially impact the company's liquidity and future investment capabilities.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 2:08 pm

In Thursday's pre-market session, several healthcare stocks showed significant movement. Agile Therapeutics, Venus Concept, and Monopar Therapeutics were among the top gainers, with stock prices increasing by 82.4%, 72.95%, and 71.91% respectively. Ocular Therapeutix, Indivior, and Apyx Medical also saw notable gains. On the downside, Synaptogenix, Motus GI Holdings, and Chemomab Therapeutics led the losers, with their stock prices falling by 20.9%, 18.19%, and 9.69% respectively. Other stocks that experienced declines include Agape ATP, China Pharma Holding, and Cadrenal Therapeutics.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 1:06 pm

NVIDIA Corporation (NASDAQ:NVDA) shares surged 14.3% in pre-market trading after reporting Q4 financial results that exceeded expectations and provided strong Q1 revenue guidance. Other stocks also moved significantly in pre-market trading, with notable gainers including Agile Therapeutics, BuzzFeed, and Elevai Labs, among others. On the losing side, Draganfly, Synaptogenix, and Bel Fuse experienced significant drops following various announcements.

Portfolio Pulse from Avi Kapoor

February 22, 2024 | 12:55 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.